Sunday, 19 March 2017

#ClinicSpeak: mode of action of B cell therapy in MS

What is missing from the anti-B-cell narrative? #ClinicSpeak #MSBlog

Will anti-B-cell therapies become the agents of choice for treating both the relapsing and advanced stages of MS. Another slick video explaining the mode of action of anti-B-cell therapies. 

What is missing? I think the narrative in this video is incomplete. Can you spot was is missing? 


CoI: multiple, the production of this video has been funded by Roche

5 comments:

  1. Have they mentioned long-lived memory B cells or was I in some sort of hypnosis-like trance and just dozed over that part?

    ReplyDelete
  2. This video reminds me of the first cell line, it made it was called BCTL-1 (Big chief Team Leader :-). It was formed by fusing B cells with a B cell tumor line.

    I worked with a guy who did EM and be put the cell in a scanner and they looked just like the cells in this video. There were loads of dots on the cell surface just like the dots on the B cells in the video. There the dots are CD20, but in my case they were virus budding from the surface. Why were the cells immortalised...I guess it was virus...indeed every mouse line I looked at, e.g. NS-1 used to make monoclonals, was hooching with live virus. I have used these cautiously every since.

    So what about HERV and EBV? Maybe they can change the colour of some dots in video mark II

    ReplyDelete
  3. Antibodies targeting myelin.....common in MS eh?

    ReplyDelete
  4. How else would this drug work then? - it is supposed to stop those new plasma cells forming and producing antibodies ... to myelin :-)

    I think I first read about it when I was an aspiring and naive young doctor (possibly in Trisha Greenhalgh book "How to Read a Paper" - and I just could not believe it ... Pharma first make a drug, test it and then if the drug seems to work, make a good story :-). Back then it was minus the 3D videos, though.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.